Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC): Metastatic Non-Small Cell Lung Cancer. - Hirsch, F.R.; Govindan, R.; Zvirbule, Z.; Braiteh, F.; Rittmeyer, A.; Belda Iniesta, C.; Isla, D.; Cosgriff, T.; Boyer, M.; Ueda, M.; Phan, S.; Gandara, D. (International Journal of Radiation Oncology, Biology, Physics, 2014)